ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(... ( ADDISON Texas Sept. 30 /- ULURU I...)

ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver

Date:9/30/2008

ADDISON, Texas, Sept. 30 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today announced that it has filed a 510k application with the United States Food and Drug Administration (FDA) for Altrazeal(TM) Silver.

Preclinical studies conducted to support the filing have shown that superior healing rates in numerous porcine wound models have been achieved relative to competitive silver dressings. Additionally, in toxicology and in vitro bacteria inhibition studies Altrazeal(TM) Silver has performed favorably relative to competitive silver dressings. This data should favorably position Altrazeal(TM) Silver in the market, providing benefits to both the patient and the health care provider.

The use of silver in wound care is increasing rapidly in the management of infected wounds and wounds at risk for infection. Silver has been used extensively as a broad-spectrum antimicrobial particularly in the treatment of chronic wounds and to manage burn infections. Wounds exhibiting increased bacterial burden have reduced healing responses when compared to wounds containing fewer bacteria.

Commenting on the 510k filing, Kerry P. Gray, President and CEO of ULURU Inc. stated, "This is an important milestone in the development of our wound care franchise. In certain wound types silver-containing products are used extensively by physicians. We have responded to a market need by developing Altrazael(TM) Silver as our sales organization has received consistent feedback from wound care practitioners that a silver containing Altrazeal(TM) is one of the products that would improve wound treatment. We expect to launch Altazeal(TM) Silver in the first quarter 2009."

In addition to being a superior wound dressing Altrazeal(TM), which incorporates our Nanoflex(TM) technology, is also a controlled drug delivery technology enabling active wound healing agents to be delivered to the wound bed over periods of up to 30 days. Altrazeal(TM) Silver is the first in a s
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. ULURU Inc. to Present at the 8th World Biomaterials Congress
2. ULURU Inc. Announces Update on Recent Development
3. ULURU Inc. Reports Second Quarter 2008 Financial Results
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter

Post Your Comments:

ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(...( ADDISON Texas Sept. 30 /- ULURU I...)